Grants & Awards
Grants
Oklahoma Center for Advancement of Science & Technology (OCAST)
2003-2006 - Implantable Hearing System
NIH Grant-Dr. Gan’s Grant
2005-2010 - Ear Biomechanics for Restoration of Hearing
INTEGRIS – Inner Ear Research
2005-06, 2006-07, 2007-08, 2008-09, 2009-10 - Acute Acoustic Trauma HPN-07 Research Project
Shulsky
2005-2006 - Maximizing Gene Delivery to the Inner Ear for Hair Cell Regeneration
Oklahoma Medical Research (OMRF)/Office of Naval Research ONR)
2005-2008 - Optimized Oral Treatment of Acute Acoustic Trauma
Office of Naval Research, 3 years
2008 - Pre-clinical study of combination oral treatment for acute acoustic trauma
Ototronix Dr. R. Kent Dyer's Temporal Bone Course
2009 - Hough Ear Institute Temporal Bone Dissection Course
Oklahoma Center for the Advancement of Science & Technology (OCAST), 2 years
2008 - Targeted Delivery of Therapeutic Nanocomposite
Hough Ear Institute (HEI) Noise Induced Hearing
2008-2010 - Cochlear Therapy through Magnetic Targeted Drug Delivery
National Institutes of Health, 2 years
2008 - Cochlear therapy through magnetic targeted drug delivery
Office of Naval Research, 3 years
2009 - Effects of Intense Noise and Blast on the central auditory pathways
Office of Naval Research, 3 years
2009 - Mechanisms and treatment of ongoing deterioration of cochlear structure and function after acute noise injury
Oklahoma Center for the Advancement of Science & Technology (OCAST), 2 years
2009 - Therapeutic protection from noise-induced hearing loss
Oklahoma Medical Research (OMRF)/Oklahoma Center for Advancement of Science & Technology (OCAST)/OARS
2009-2011 - Targeted Delivery of Therapeutics by Magnetic Nanoparticles to the Inner Ear
Cochlear Americas, Inc. 2 years
2010 - Protection from cochlea implant trauma using nanoparticles for drug delivery
Quark
2011-2013 - siRNA targeting Notch pathway
Office of Naval Research, 1 year
2012 - Therapeutic for the Treatment and Prevention of Noise-Induced Hearing Loss
USA Medical Research ACQ Activity, 2 years
2013 - Phase 1 Clinical Trial for a Novel, Orally Available, Therapeutic that Addresses Noise-Induced Hearing Loss
Naval Medical Logistics Command, 2 years
2012 - Development of a FDA-Approved Pharmaceutical to Treat Noise-Induced Hearing Loss
NIH-Gan
2012-2016 - Biomedical measurement and modeling of normal and diseased middle ear
Naval Medical Logistics Command, 1 year
2013 – NHPN-1010 for the treatment of Noise Induced Hearing Loss Toxicology study required for IND
Otologic Pharmaceutics Inc. (OPI)-Cisplatin
2014- Does HPN-07 alone or in combination with NAC block cisplating-induced hearing loss and hair cell dealth (in vivo)
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
2015-2016 - Novel Therapeutic Treatment for Tinnitus, Hyperacusis and Brain Injury
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
2015-2017 – Characterization of Cochlear Hair Cell Regeneration Through Knockdown of the HES1 Gene Product in Mice After Noise-Induced Deafness
Oklahoma Center for the Advancement of Science and Technology (OCAST)/HR
2015-2017 – Restoring Synaptic Connections in the Cochlea Using a Novel Brain Metabolite
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
2017-2019 – Prophylactic Treatment for Cisplatin-Induced Ototoxicity
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
2018-2019 – NHPN-1010 treatment of chronic tinnitus
US Army Medical Research Acquisition Activity (USAMRAA)
2018-2021 – Novel Therapeutic for Cochlear Hair Cell Regeneration and Hearing Restoration
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
Oklahoma Center for the Advancement of Science and Technology (OCAST)/OARS
2020-2022 – Advancement of a novel therapeutic for reversing clinical indicators of cochlear synaptopathy and tinnitus